BR112016002317A2 - métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumab - Google Patents

métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumab

Info

Publication number
BR112016002317A2
BR112016002317A2 BR112016002317A BR112016002317A BR112016002317A2 BR 112016002317 A2 BR112016002317 A2 BR 112016002317A2 BR 112016002317 A BR112016002317 A BR 112016002317A BR 112016002317 A BR112016002317 A BR 112016002317A BR 112016002317 A2 BR112016002317 A2 BR 112016002317A2
Authority
BR
Brazil
Prior art keywords
benralizumab
methods
asthmatics
expiratory volume
forced expiratory
Prior art date
Application number
BR112016002317A
Other languages
English (en)
Other versions
BR112016002317A8 (pt
Inventor
Wang Bing
Ward Christine
Raible Donald
Roskos Lorin
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BR112016002317A2 publication Critical patent/BR112016002317A2/pt
Publication of BR112016002317A8 publication Critical patent/BR112016002317A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)

Abstract

a invenção refere-se a métodos para aumento do volume expiratório forçado em um segundo (fev1) em um paciente com asma, compreendendo a administração ao paciente de uma quantidade eficaz de benralizumab ou de um seu fragmento de ligação ao antígeno.
BR112016002317A 2013-08-12 2014-08-07 Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos BR112016002317A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
PCT/US2014/050119 WO2015023507A2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Publications (2)

Publication Number Publication Date
BR112016002317A2 true BR112016002317A2 (pt) 2017-12-12
BR112016002317A8 BR112016002317A8 (pt) 2018-06-12

Family

ID=52448838

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002317A BR112016002317A8 (pt) 2013-08-12 2014-08-07 Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos

Country Status (25)

Country Link
US (1) US9441046B2 (pt)
EP (3) EP3520811B1 (pt)
JP (3) JP6746496B2 (pt)
KR (1) KR102337599B1 (pt)
CN (2) CN111588849A (pt)
AU (2) AU2014306959B2 (pt)
BR (1) BR112016002317A8 (pt)
CA (1) CA2917603C (pt)
CY (2) CY1122033T1 (pt)
DK (2) DK3520811T3 (pt)
ES (2) ES2866426T3 (pt)
HK (2) HK1222559A1 (pt)
HR (2) HRP20190920T1 (pt)
HU (2) HUE043497T2 (pt)
LT (2) LT3033104T (pt)
ME (1) ME03403B (pt)
MX (2) MX2016001384A (pt)
PL (2) PL3520811T3 (pt)
PT (2) PT3033104T (pt)
RS (2) RS61565B1 (pt)
RU (1) RU2703568C2 (pt)
SG (1) SG11201600483QA (pt)
SI (2) SI3520811T1 (pt)
TR (1) TR201907907T4 (pt)
WO (1) WO2015023507A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2676333C2 (ru) * 2013-08-12 2018-12-28 Астразенека Аб Способы снижения частоты приступов астмы с применением бенрализумаба
JP6803229B2 (ja) * 2013-08-12 2020-12-23 アストラゼネカ アクチボラグ ベンラリツマブによる喘息症状の改善方法
JP2016534996A (ja) * 2013-10-15 2016-11-10 メディミューン，エルエルシー ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
CN105611938A (zh) * 2013-10-24 2016-05-25 免疫医疗有限责任公司 稳定的水性抗体配制品
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2205007C (en) 1995-09-11 2010-12-14 Masamichi Koike Antibody against human interleukin-5 receptor .alpha. chain
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
ES2420835T3 (es) 1999-04-09 2013-08-27 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de las moléculas inmunofuncionales
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1688437A4 (en) 2003-10-08 2007-09-26 Kyowa Hakko Kogyo Kk SPECIALLY BINDING ANTIBODY COMPOSITION TO IL-5 RECEPTOR
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
EP2068927B1 (en) * 2007-05-14 2015-10-21 MedImmune, LLC Methods of reducing eosinophil levels
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
KR101615474B1 (ko) * 2010-12-16 2016-04-25 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
WO2013066780A2 (en) * 2011-11-01 2013-05-10 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
RU2676333C2 (ru) * 2013-08-12 2018-12-28 Астразенека Аб Способы снижения частоты приступов астмы с применением бенрализумаба
JP6803229B2 (ja) * 2013-08-12 2020-12-23 アストラゼネカ アクチボラグ ベンラリツマブによる喘息症状の改善方法

Also Published As

Publication number Publication date
JP2022120010A (ja) 2022-08-17
ES2866426T3 (es) 2021-10-19
EP3875487A1 (en) 2021-09-08
ME03403B (me) 2020-01-20
LT3033104T (lt) 2019-06-25
SI3520811T1 (sl) 2021-04-30
EP3033104B1 (en) 2019-04-03
DK3033104T3 (da) 2019-06-17
MX2016001384A (es) 2016-08-03
AU2020201277A1 (en) 2020-03-12
PL3520811T3 (pl) 2021-08-02
SI3033104T1 (sl) 2019-06-28
EP3033104A2 (en) 2016-06-22
EP3520811B1 (en) 2020-12-30
JP2020125304A (ja) 2020-08-20
HK1222559A1 (zh) 2017-07-07
HK1225300A1 (zh) 2017-09-08
WO2015023507A3 (en) 2015-04-09
CN105451769A (zh) 2016-03-30
RS58711B1 (sr) 2019-06-28
AU2014306959B2 (en) 2019-11-21
HUE043497T2 (hu) 2019-08-28
PT3033104T (pt) 2019-06-27
KR20160043049A (ko) 2016-04-20
DK3520811T3 (da) 2021-03-22
KR102337599B1 (ko) 2021-12-10
EP3033104A4 (en) 2017-03-22
CA2917603A1 (en) 2015-02-19
PL3033104T3 (pl) 2019-09-30
HRP20210406T1 (hr) 2021-04-30
TR201907907T4 (tr) 2019-06-21
JP6746496B2 (ja) 2020-08-26
CY1124399T1 (el) 2022-07-22
EP3520811A1 (en) 2019-08-07
MX2021003826A (es) 2021-05-27
ES2733602T3 (es) 2019-12-02
CN111588849A (zh) 2020-08-28
WO2015023507A2 (en) 2015-02-19
CA2917603C (en) 2023-05-16
RU2016108809A (ru) 2017-09-18
BR112016002317A8 (pt) 2018-06-12
PT3520811T (pt) 2021-03-15
US20150044203A1 (en) 2015-02-12
AU2014306959A1 (en) 2016-02-04
US9441046B2 (en) 2016-09-13
RS61565B1 (sr) 2021-04-29
HUE053627T2 (hu) 2021-07-28
JP2016527325A (ja) 2016-09-08
HRP20190920T1 (hr) 2019-07-12
WO2015023507A8 (en) 2015-09-24
RU2703568C2 (ru) 2019-10-21
SG11201600483QA (en) 2016-02-26
CY1122033T1 (el) 2020-10-14
LT3520811T (lt) 2021-03-25
RU2016108809A3 (pt) 2018-06-18

Similar Documents

Publication Publication Date Title
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
BR112016002317A2 (pt) métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumab
BR112014008294A2 (pt) anticorpo anti c-met e usos do mesmo
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
EA201591166A1 (ru) Ингибиторы аутотаксина
BR112014032990A2 (pt) seringa
EA201590554A1 (ru) Ингибиторы глюкозилцерамид-синтазы
AU2011328009A8 (en) Compounds and methods for treating pain
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
EA201491581A1 (ru) Везикулярные композиции
BR112015017432A2 (pt) métodos para o tratamento de indicações cardiovasculares
WO2013163562A3 (en) Compositions and methods for treating ptsd and related diseases
MX2015000777A (es) Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular..
UA113065C2 (xx) Композиція для нанесення на шкіру та її застосування
BR112017012931A2 (pt) métodos para redução de agregação plaquetária e tratamento de doença cardiovascular e outros distúrbios médicos
TR201106224A2 (tr) Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler.
BR112013032188A2 (pt) composição, produto e método para tratar pacientes com hepatite c crônica
MX369774B (es) Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos.
BR112015003815A2 (pt) métodos e composições para o tratamento de uma condição genética

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ASTRAZENECA AB (SE)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ASTRAZENECA AB (SE)

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.